PRODUCTID|PRODUCTNDC|PRODUCTTYPENAME|PROPRIETARYNAME|PROPRIETARYNAMESUFFIX|NONPROPRIETARYNAME|DOSAGEFORMNAME|ROUTENAME|STARTMARKETINGDATE|ENDMARKETINGDATE|MARKETINGCATEGORYNAME|APPLICATIONNUMBER|LABELERNAME|SUBSTANCENAME|ACTIVE_NUMERATOR_STRENGTH|ACTIVE_INGRED_UNIT|PHARM_CLASSES|DEASCHEDULE|NDC_EXCLUDE_FLAG|LISTING_RECORD_CERTIFIED_THROUGH|GenBrandFlag|RxClass|NDCCODE|PACKAGE_PRODUCTID|PACKAGE_PRODUCTNDC|PACKAGEDESCRIPTION|PACKAGE_STARTMARKETINGDATE|PACKAGE_ENDMARKETINGDATE|PACKAGE_NDC_EXCLUDE_FLAG|SAMPLE_PACKAGE|classification_for_rate_setting
0002-3182_02015dc8-99de-47b3-b543-5b2a6db567b7|0002-3182|HUMAN PRESCRIPTION DRUG|Trulicity|""|Dulaglutide|INJECTION, SOLUTION|SUBCUTANEOUS|20200903|""|BLA|BLA125469|Eli Lilly and Company|DULAGLUTIDE|4.5|mg/.5mL|GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]|""|N|20231231|B|GLP-1 Receptor Agonist|00002318261|0002-3182_02015dc8-99de-47b3-b543-5b2a6db567b7|0002-3182|2 SYRINGE in 1 CARTON (0002-3182-61)  > .5 mL in 1 SYRINGE|20200930|""|N|Y|""
0002-3182_02015dc8-99de-47b3-b543-5b2a6db567b7|0002-3182|HUMAN PRESCRIPTION DRUG|Trulicity|""|Dulaglutide|INJECTION, SOLUTION|SUBCUTANEOUS|20200903|""|BLA|BLA125469|Eli Lilly and Company|DULAGLUTIDE|4.5|mg/.5mL|GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]|""|N|20231231|B|GLP-1 Receptor Agonist|00002318280|0002-3182_02015dc8-99de-47b3-b543-5b2a6db567b7|0002-3182|4 SYRINGE in 1 CARTON (0002-3182-80)  > .5 mL in 1 SYRINGE (0002-3182-01)|20200903|""|N|N|B
0002-3250_6963b20c-fce1-414e-90b6-5d0730f93191|0002-3250|HUMAN PRESCRIPTION DRUG|Strattera|""|Atomoxetine hydrochloride|CAPSULE|ORAL|20050214|""|NDA|NDA021411|Eli Lilly and Company|ATOMOXETINE HYDROCHLORIDE|80|mg/1|Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]|""|N|20231231|B|Norepinephrine Reuptake Inhibitor|00002325030|0002-3250_6963b20c-fce1-414e-90b6-5d0730f93191|0002-3250|30 CAPSULE in 1 BOTTLE (0002-3250-30)|20050824|""|N|N|B